Pharmaceutical company Endo is terminating its agreement with Acerus Pharmaceuticals Corporation to market the nasal testosterone treatment NATESTO in the United States, effective June 30, 2016. NATESTO was approved in May 2014 and is the first and only testosterone nasal spray gel sold in the U.S. for the treatment of hypogonadism, a condition in which men do not produce enough testosterone due to injury or disease. The gel is available as a metered dose pump containing 60 actuations. Each pump delivers 5.5mg of testosterone in 0.122g gel. “While we are disappointed with Endo’s previously announced strategic business decision to realign their U.S. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.